Advancing Therapy in Basal Insulin-Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI

被引：0
|
作者：
Home, Philip
McCrimmon, Rory J.
Rosenstock, Julio
Bluher, Matthias
Pegelow, Katrin
Melas-Melt, Lydie
Djaballah, Khier
Giorgino, Francesco
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-845-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
845-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Advancing Therapy in Basal Insulin-Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function
    Home, Philip
    Rosenstock, Julio
    Giorgino, Francesco
    Bluher, Matthias
    Djaballah, Khier
    Pegelow, Katrin
    Melas-Melt, Lydie
    DIABETES, 2022, 71
  • [2] Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial
    Mccrimmon, Rory J.
    Home, Philip
    Cheng, Alice Y.
    Giorgino, Francesco
    Fonseca, Vivian
    Souhami, Elisabeth
    Alvarez, Agustina
    Boss, Anders H.
    Melas-Melt, Lydie
    Rosenstock, Julio
    DIABETES, 2021, 70
  • [3] Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial
    Mccrimmon, Rory J.
    Cheng, Alice Y.
    Fonseca, Vivian
    Choza, Ricardo
    Alessa, Thamer
    Alvarez, Agustina
    Souhami, Elisabeth
    Boss, Anders H.
    Picard, Pascaline
    Rosenstock, Julio
    DIABETES, 2021, 70
  • [4] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial
    McCrimmon, Rory J.
    Al Sifri, Saud
    Emral, Rifat
    Mohan, Viswanathan
    Sauque-Reyna, Leobardo
    Trescoli, Carlos
    Lalic, Nebojsa
    Alvarez, Agustina
    Demil, Nacima
    Coudert, Mathieu
    Shaunik, Alka
    Bonnemaire, Mireille
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2021, 23 (06): : 1221 - 1231
  • [5] Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
    Frechtel, Gustavo
    Sauque-Reyna, Leobardo
    Choza-Romero, Ricardo
    Anguiano, Luis
    Melas-Melt, Lydie
    Sanudo-Maury, Maria Elena
    DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2526 - 2534
  • [6] Relationship of baseline HbA1c and HbA1c reduction following insulin therapy in Type 2 diabetes
    Giugliano, D.
    Esposito, K.
    DIABETIC MEDICINE, 2011, 28 (02) : 247 - 247
  • [7] Impact of hypoglycaemia on insulin titration and fasting plasma glucose in basal insulin-treated type 2 diabetes: a subanalysis of the SoliMix trial
    Ritzel, R.
    McCrimmon, R. J.
    Rosenstock, J.
    Deyneli, O.
    Alvarez, A.
    Souhami, E.
    Melas-Melt, L.
    Giorgino, F.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S328 - S328
  • [8] Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin-Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial
    Giorgino, Francesco
    Rosenstock, Julio
    Ritzel, Robert
    Deyneli, Oguzhan
    Alvarez, Agustina
    Souhami, Elisabeth
    Melas-Melt, Lydie
    McCrimmon, Rory J.
    DIABETES, 2022, 71
  • [9] Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
    Rosenstock, Julio
    Emral, Rifat
    Sauque-Reyna, Leobardo
    Mohan, Viswanathan
    Trescoli, Carlos
    Al Sifri, Saud
    Lalic, Nebojsa
    Alvarez, Agustina
    Picard, Pascaline
    Bonnemaire, Mireille
    Demil, Nacima
    McCrimmon, Rory J.
    DIABETES CARE, 2021, 44 (10) : 2361 - 2370
  • [10] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial (vol 23, pg 1221, 2021)
    McCrimmon, R. J.
    Al Sifri, S.
    Emral, R.
    DIABETES OBESITY & METABOLISM, 2021, 23 (11): : 2600 - 2600
12345